Pediatrics

Take a look back at our most popular pediatric coverage for 2022.

The US Food and Drug Administration has updated the emergency use authorization for bivalent COVID-19 vaccines to be available for children aged 6 months and older.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

Cost savings were not associated with an increase in adverse drug events.

Not every pharmacist may feel comfortable administering vaccines to children, but education could help.

Shortages are leaving patients in the lurch.

The US was the first country to begin universal vaccination of children against varicella.

Additional research is needed to fully understand the scope of Long COVID.

Aro Biotherapeutics’ ABX1100, used to treat Pompe disease, was granted a Rare Pediatric Drug designation by the FDA.

William J. Muller, MD, PhD, discusses COVID-19 vaccinations for children of all ages and describes what is on the horizon for RSV.

Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.

Software updates in closed-loop systems may lead to better time in range numbers for children with type 1 diabetes.

Are prescription cap laws for opioids effective for children and teenagers?

Improved glycemic control could reduce the risk of diabetes-related brain damage among teens and adolescents with type 1 diabetes.

Findings show more than one-third of infected preschoolers are asymptomatic. The results call into question COVID-19 prevention strategies based on screening young children for symptoms.

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

Clearance expands on initial clearance from January 2022.

Children with atopic dermatitis will soon have more options for treatment, as clinical trials show promising results.

A variety of nonprescription treatments, supplements, and patches can alleviate pain for children and adolescents.

Further evidence-based antidepressant treatments are needed for children and adolescents with depression.

The FDA has granted Emergency Use Authorization EUA of the Jynneos vaccine for pediatric patients <18 years who are at high risk of monkeypox infection.

Pharmacists’ body of knowledge is crucial in helping pediatric and adult patients select the right medication to treat their ADHD.

Evidence of the relationship between probiotics and antibiotics is lacking.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

There are numerous methods of contraception available for adolescents.